IONS (Ionis Pharmaceuticals, Inc.) Return on Gross Profit

Corporate emblem and logo of Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals (IONS) generates revenue through royalties from RNA therapy partnerships. Diversifying its drug portfolio across various pathologies mitigates financial risks, while the growth of its user base depends on FDA approvals. Production margins demonstrate cost efficiency, where the 95.40 level serves as the current metric, confirming the company's ability to maintain profits amid fluctuations in cost of goods sold.

Return on Gross Profit: Ionis Pharmaceuticals (IONS) for 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for ionispharma.com (IONS)

- market value and analyst target forecast:
- business market valuation indicators:
Fundamental valuation:IONS, Ionis
Flagship merchandise of Ionis Pharmaceuticals

To build a portfolio of high-quality assets, I evaluate cost management efficiency via the gross margin. This ratio determines the profit share after deducting direct production costs, measuring the business's fundamental ability to generate cash flow. For Ionis Pharmaceuticals (IONS), its status as an RNA therapy innovator allows it to maintain high product pricing due to the uniqueness of its platforms. Analyzing sales margins helps identify overvaluation risks or buy signals in a timely manner.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Repligen Inc. - Gross Profitability Margin|Gross Margin RNA|CRSP - Gross Profit Margin|GeneDx - Return on Gross Profit|Gross Profit Rate RARE|Beam Tx - Gross Margin|SRPT - Gross Margin|TWST (Twist Bio) - Return on Gross Profit|Gross Return on Sales TXG|Return on Gross Profit NTLA|Stoke Therapeutics Inc (STOK) - Return on Sales by Gross Profit|Gross Margin BLFS|Gross Profitability WVE (Wave Life Sciences Corp)|Gross Profitability Maze Therapeutics MAZE|Gross Profit Rate SION|PRME - Gross Profitability|Return on Sales by Gross Profit Taysha TSHA|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability